Najat Khan Sells 22,408 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 22,408 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the transaction, the chief executive officer owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. The trade was a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $3.20 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $2.77 and a 1 year high of $7.18. The firm has a 50 day moving average price of $3.29 and a 200 day moving average price of $3.33. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -3.08 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The company had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $10.97 million. During the same period in the prior year, the business earned ($0.41) EPS. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. MCF Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at about $27,000. International Assets Investment Management LLC acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $31,000. Integral Investment Advisors Inc. purchased a new position in Recursion Pharmaceuticals in the 1st quarter worth approximately $39,000. Sequoia Financial Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $41,000. Finally, MQS Management LLC purchased a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at approximately $41,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on RXRX shares. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Finally, Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a research note on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.06.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.